ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 959

Discoid Lupus Onset and Decrease Risk of Renal Disease in Patients with Systemic Lupus Erythematosus: Data from a Large Latin American Cohort

Guillermo J. Pons-Estel1, Gaobin Bao2, Bernado Pons-Estel3, Daniel Wojdyla4, Veronica Saurit5,6, Alejandro J. Alvarellos7, Francisco Caeiro8, Emilia I. Sato9, Enrique R. Soriano10, Lilian Tereza Costallat11, Oscar Neira12, Antonio A. Iglesias-Gamarra13, Gil Reyes Llerena14, Mario Cardiel15, Eduardo M. Acevedo-Vásquez16, Rosa Chacon17 and Cristina M. Drenkard18, 1Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 2Medicine, Emory University, Atlanta, GA, 3Hospital Provincial de Rosario, Rosario, Argentina, 4Universidad Nacional de Rosario, Argentina, Rosario, Argentina, 5Rheumatology, Hospital Privado Córdoba, Cordoba, Argentina, 6Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, 7Reumatología, Hospital Privado Córdoba, Córdoba, Argentina, 8Naciones Unidas 346, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 9Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 10Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 11RUA EZEQUIEL MAGALHAES,26, Unicamp, Campinas, Brazil, 12Rheumatology Section, Univ of Chile Hosp Salvador, Santiago, Chile, 13Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor-Universidad Nacional de Colombia, Bogota, Colombia, 14Servicio Nacional de Reumatología, Centro de Investigaciones Médico Quirúrgicas (CIMEQ), La Habana, Cuba, 15Unidad de Investigación ‘Dr. Mario Alvizouri Muñoz’, Secretaría de Salud de Michoacán, Morelia, Mexico, 16Rheumatology, Hospital Nacional “Guillermo Almenara Irigoyen”, Lima, Peru, 17Servicio de Reumatología, Hospital Universitario, Centro Nacional de Enfermedades Reumáticas and Hospital de Clínicas Caracas, Caracas, Venezuela, 18Medicine, Div Rheumatology, Emory University, Atlanta, GA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis

Session Type: Abstract Submissions (ACR)

Background/Purpose .Early data derived from small selected samples suggest that discoid lupus erythematosus (DLE) is negatively associated with renal involvement in patients with SLE. Recent findings from two large transversal studies are controversial, and the prognosis value of DLE on renal disease remains unclear. We used a longitudinal design to examine whether DLE onset protects against the development of LN in patients with systemic lupus erythematosus SLE from a large multiethnic Latin-American cohort.

Methods . We studied SLE patients enrolled in GLADEL, an inception longitudinal cohort from 34 centers in 9 Latin American countries. The main predictor was DLE onset, which was defined as physician-documented DLE that occurred before the diagnosis of SLE. The outcome was time from the diagnosis of SLE to LN during the followup. LN was defined by clinical or histological documentation of lupus glomerulonephritis or renal insufficiency secondary to LN.  Kaplan-Meier analysis and Cox proportional hazard models were used to examine the association between DLE onset and time to LN.

Results . We examined 891 GLADEL SLE patients at risk (91% females and 56% non-Caucasians). The mean age at SLE diagnosis and mean duration of follow-up were 30.8 years (SD 12.6) and 4.3 years (SD 2.3), respectively. Overall, 56 patients had DLE onset, and 329 developed LN during the followup. Among the LN group, only 10 (3.0%) had DLE onset, compared to 46 (8.2%) in the group that remained free of LN (p<0.0023). The cumulative proportion of LN at 1- and 5-year since SLE diagnosis was 12% and 24%, respectively in the DLE onset group, compared to 23% and 42% in those without DLE (p<0.0019) (Figure). Table 1 shows that DLE onset was negatively associated with time-to-LN after controlling for potential confounders. The final predictive model shows that the hazard ratio (HR) of LN in patients with DLE onset was 0.47 (95% CI 0.23–0.96) after controlling sociodemographic factors and disease severity at diagnosis.

Conclusion .Our data from the largest Latin-American SLE cohort indicate that the presence of DLE before the diagnosis of SLE protects against further LN, independently of other contributing factors such as age, ethnicity and SLE severity. These findings have relevant prognosis implications to SLE patients and their clinicians. Further studies are warranted to unravel the biological and environmental pathways implicated in the protective role of DLE against renal disease in patients with SLE.


Disclosure:

G. J. Pons-Estel,
None;

G. Bao,

GlaxoSmithKline,

2;

B. Pons-Estel,
None;

D. Wojdyla,
None;

V. Saurit,
None;

A. J. Alvarellos,
None;

F. Caeiro,
None;

E. I. Sato,
None;

E. R. Soriano,
None;

L. T. Costallat,
None;

O. Neira,
None;

A. A. Iglesias-Gamarra,
None;

G. Reyes Llerena,
None;

M. Cardiel,
None;

E. M. Acevedo-Vásquez,
None;

R. Chacon,
None;

C. M. Drenkard,

NIH,

2,

GlaxoSmithKline,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discoid-lupus-onset-and-decrease-risk-of-renal-disease-in-patients-with-systemic-lupus-erythematosus-data-from-a-large-latin-american-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology